In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Jacob JensenDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States.ORCID 0009-0004-8146-388X Marcela CunhaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States.ORCID 0009-0000-0913-1347 Broti AdhikaryDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States.ORCID 0009-0006-6796-2804 Iszavier MoeDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States.ORCID 0009-0007-0712-0215 Jasmine BeldinDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States.
Luiza MendonçaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States.ORCID 0000-0002-9210-9139 Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8MThe Midwest Center for Cryo-Electron TomographyU24GM139168 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI WRIGHT, ELIZABETH R · 2020 to 2025
$41.7MStructural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Alan N. Engelman · 2022 to 2026
$36.7MProject 3 - Dynamics of latent HIV-1 reservoirs: High resolution antigenic mapping and strategies to block reboundU54AI170752 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2022 to 2026
$32.0MPathways in Biological Sciences Training ProgramT32GM133351 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Matthew Daugherty, Randolph Y. Hampton · 2020 to 2026
$9.9MFunctionally Defining HIV-Host Interactions During the Early HIV-1 LifecycleR01AI150998 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIENIASZ, PAUL D., HOPE, THOMAS · 2020 to 2024
$6.8MStructural basis for activity of and resistance to HIV integrase inhibitorsU01AI136680 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI LYUMKIS, DMITRY · 2022 to 2025
$3.4MMinnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2MMechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation modelsR01AI178849 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI Ronald Levy · 2023 to 2026
$2.7MRole of HIV-1 integrase in virion morphogenesis and its targeting by allosteric integrase inhibitorsR01AI184419 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JAMES R FUCHS, Sebla B. Kutluay · 2024 to 2026
$2.4MMolecular Pathways Leading to Drug Resistance in HIV-1 IntegraseR21AI197945 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Dmitry Lyumkis · 2026 to 2026
$516kNCI NIH HHS P30 CA014195NCI NIH HHS P30 CA014520NIAID NIH HHS R01 AI150998NIAID NIH HHS R01 AI178849NIAID NIH HHS R01 AI184419NIAID NIH HHS R21 AI191967NIAID NIH HHS R21 AI197945NIAID NIH HHS T32 AI083196NIAID NIH HHS U01 AI136680NIAID NIH HHS U54 AI170752NIAID NIH HHS U54 AI170855NIGMS NIH HHS T32 GM133351NIGMS NIH HHS U24 GM139168
6 · The paper itselfAbstract
Cell-cell transmission of HIV-1 (CCT) is a highly efficient mode of intrahost transmission that provides viral particles broad protection from antiretroviral agents including antiretroviral drugs, host restriction factors, and broadly neutralizing antibodies. Interestingly, the exact factors that grant viral particles increased protection and efficiency during intrahost spread remain unclear. Using a T cell co-culturing system and correlative cryoelectron tomography (cryoET) workflow, we investigated the architecture of HIV-1 CCT sites in a near-native,
Identifiers
PMID42327053
PMCPMC13278146
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390